{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-072556","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2022-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.929675+00:00","generated_at":"2026-06-21T18:27:04.984432+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adial Pharma Q3 net loss narrows to $3.1M; CEO promoted, AD04 regulatory submission in progress","bullets":["Net loss of $3.1M ($0.12/shr) vs $4.3M ($0.22/shr) in Q3 2021.","Cash and equivalents $5.8M as of Sep 30, 2022, from $6.1M at Dec 31, 2021.","R&D expenses fell 26% to $1.3M; G&A expenses fell 18% to $1.9M vs year-ago quarter.","Cary Claiborne promoted to President and CEO; William Stilley named CEO of Purnovate subsidiary.","Advancing AD04 ONWARD Phase 3 results to regulators; active partnership discussions for AD04 and Purnovate compounds."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-072556","json":"https://secwatch.observer/filing/0001213900-22-072556.json","markdown":"https://secwatch.observer/filing/0001213900-22-072556.md","text":"https://secwatch.observer/filing/0001213900-22-072556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390022072556/0001213900-22-072556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390022072556/ea168662-8k_adialpharm.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T18:27:04.984432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"108d4561433ab24e93a43ad86bfd70a6aa881c53","claim":"ADIAL PHARMACEUTICALS, INC. reported third quarter of 2022 results: net income $3.1 million, EPS $0.12.","evidence_excerpt":"Net Loss was $3.1 million for the third quarter of 2022 as compared to a net loss of $4.3 million in the third quarter of 2021. Net loss per share for the third quarter of 2022 was $0.12, compared to a net loss of $0.22 per share for the third quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390022072556/0001213900-22-072556-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2022"},{"label":"Net income","value":"$3.1 million"},{"label":"EPS","value":"$0.12"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}